MCID: LKM060
MIFTS: 53

Leukemia, Acute Lymphoblastic 3

Categories: Genetic diseases, Blood diseases, Rare diseases, Immune diseases, Cancer diseases

Aliases & Classifications for Leukemia, Acute Lymphoblastic 3

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic 3:

Name: Leukemia, Acute Lymphoblastic 3 57
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 57 29 6 40 73
B-All 59 55
Precursor B-Cell Acute Lymphoblastic Leukemia/lymphoma 59
Precursor B-Cell Acute Lymphocytic Leukemia/lymphoma 59
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 73
Precursor B-Cell Acute Lymphoblastic Leukemia 59
Precursor B-Cell Acute Lymphocytic Leukemia 59
Precursor B-Cell Lymphoblastic Leukemia 73
Burkitt Lymphoma 73
All3 57

Classifications:



External Ids:

OMIM 57 615545
Orphanet 59 ORPHA99860
ICD10 via Orphanet 34 C91.0 C83.5
UMLS via Orphanet 74 C0006413 C1292769
MedGen 42 C3809874

Summaries for Leukemia, Acute Lymphoblastic 3

MalaCards based summary : Leukemia, Acute Lymphoblastic 3, also known as leukemia, acute lymphoblastic, susceptibility to, 3, is related to leukemia, acute lymphoblastic and acute lymphocytic leukemia, and has symptoms including bone pain An important gene associated with Leukemia, Acute Lymphoblastic 3 is PAX5 (Paired Box 5), and among its related pathways/superpathways are Endometrial cancer and NF-kappaB Signaling. The drugs Tranexamic Acid and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include b cells, brain and testes, and related phenotypes are Decreased viability and Decreased viability

Description from OMIM: 615545

Related Diseases for Leukemia, Acute Lymphoblastic 3

Diseases in the Lymphoblastic Leukemia family:

Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic 2
Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 32.5 ABL1 AFF1 BCR ETV6 FLT3 IGH
2 acute lymphocytic leukemia 30.8 BCR CDKN2A ETV6 PAX5 RUNX1 TP53
3 leukemia 29.8 ABL1 BCR ETV6 FLT3 HLF PBX1
4 lymphoblastic leukemia 29.1 ABL1 AFF1 BCR CDKN2A ETV6 FLT3
5 ring chromosome 21 11.1 ETV6 KMT2A
6 philadelphia-negative chronic myeloid leukemia 11.0 ABL1 BCR
7 primary hypereosinophilic syndrome 11.0 ETV6 PDGFRA
8 acute myeloid leukemia with t(8;21)(q22;q22) translocation 11.0 FLT3 RUNX1
9 platelet disorder, familial, with associated myeloid malignancy 11.0 ETV6 RUNX1
10 mn1 10.9 ETV6 FLT3 KMT2A
11 lymphoid leukemia 10.9 ETV6 FLT3 KMT2A
12 b-cell adult acute lymphocytic leukemia 10.9 ABL1 PAX5 PBX1
13 myeloid sarcoma 10.9 FLT3 KMT2A PAX5
14 brain stem astrocytic neoplasm 10.9 CDKN2A TP53
15 b-cell childhood acute lymphoblastic leukemia 10.9 ETV6 RUNX1
16 cellular neurofibroma 10.9 ABL1 TP53
17 8p11 myeloproliferative syndrome 10.8 BCR FLT3 RUNX1
18 loeffler endocarditis 10.8 ETV6 PDGFRA
19 acute lymphoblastic leukemia, childhood 10.8 CDKN2A ETV6 RUNX1
20 inverted transitional papilloma 10.8 CDKN2A GATA3
21 chronic eosinophilic leukemia 10.8 ABL1 FLT3 PDGFRA
22 chronic myelomonocytic leukemia 10.8 ETV6 FLT3 RUNX1
23 atypical chronic myeloid leukemia 10.8 ABL1 PDGFRA RUNX1
24 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.8 ETV6 FLT3 KMT2A RUNX1
25 cytogenetically normal acute myeloid leukemia 10.7 FLT3 KMT2A
26 myeloproliferative neoplasm 10.7 ABL1 BCR PDGFRA
27 central nervous system lymphoma 10.7 CDKN2A FOXP1 TP53
28 grade iii astrocytoma 10.7 CDKN2A PDGFRA TP53
29 bartholin's duct cyst 10.7 GATA3 TP53
30 keratinizing squamous cell carcinoma 10.7 CDKN2A TP53
31 mantle cell lymphoma 10.7 CDKN2A IGH PAX5 TP53
32 differentiated thyroid carcinoma 10.6 CDKN2A ETV6 TP53
33 chordoma 10.6 CDKN2A PDGFRA TP53
34 spitz nevus 10.6 CDKN2A TP53
35 b-cell lymphomas 10.6 CDKN2A FOXP1 PAX5 TP53
36 malignant peripheral nerve sheath tumor 10.5 CDKN2A PDGFRA TP53
37 lymphoma, non-hodgkin, familial 10.5 BCR IGH PAX5 TP53
38 gastrointestinal system cancer 10.5 CDKN2A PDGFRA TP53
39 oligodendroglioma 10.5 CDKN2A PDGFRA TP53
40 gastrointestinal stromal tumor 10.4 ABL1 CDKN2A FLT3 PDGFRA TP53
41 mixed glioma 10.3 PDGFRA TP53
42 bone marrow cancer 10.3 ABL1 BCR ETV6 FLT3 PDGFRA RUNX1
43 precursor t-cell acute lymphoblastic leukemia 10.3 ABL1 BCR CDKN2A ETV6 FLT3 IGH
44 myelodysplastic syndrome 10.3 ABL1 ETV6 FLT3 KMT2A RUNX1 TP53
45 myeloid leukemia 10.3 ABL1 BCR ETV6 FLT3 RUNX1 TP53
46 acute leukemia 10.2 AFF1 ETV6 FLT3 KMT2A PAX5 RUNX1
47 leukemia, chronic myeloid 10.2 ABL1 BCR ETV6 FLT3 KMT2A PDGFRA
48 bladder carcinoma in situ 10.1 CDKN2A TP53
49 childhood leukemia 10.1 ABL1 ETV6 KMT2A PBX1 RUNX1 TCF3
50 hematologic cancer 10.0 ABL1 BCR ETV6 FLT3 KMT2A PAX5

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic 3:



Diseases related to Leukemia, Acute Lymphoblastic 3

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic 3

Clinical features from OMIM:

615545

UMLS symptoms related to Leukemia, Acute Lymphoblastic 3:


bone pain

GenomeRNAi Phenotypes related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.99 BCR
2 Decreased viability GR00173-A 9.99 PDGFRA FLT3
3 Decreased viability GR00221-A-1 9.99 ABL1 PDGFRA PIP4K2A CDKN2A FLT3
4 Decreased viability GR00221-A-2 9.99 ABL1 BCR
5 Decreased viability GR00221-A-3 9.99 PDGFRA ABL1 CDKN2A
6 Decreased viability GR00221-A-4 9.99 PDGFRA BCR PIP4K2A CDKN2A FLT3
7 Decreased viability GR00301-A 9.99 BCR PIP4K2A
8 Decreased viability GR00342-S-1 9.99 ABL1
9 Decreased viability GR00342-S-2 9.99 ABL1
10 Decreased viability GR00342-S-3 9.99 BCR ABL1
11 Decreased viability GR00402-S-2 9.99 PDGFRA BCR PIP4K2A CDKN2A FLT3 ABL1

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic 3:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.44 CDKN2A AFF1 AUTS2 ABL1 BCR ETV6
2 cellular MP:0005384 10.43 ABL1 BCR CDKN2A AUTS2 ETV6 FLT3
3 behavior/neurological MP:0005386 10.37 BCR ABL1 AFF1 CDKN2A AUTS2 HLF
4 hematopoietic system MP:0005397 10.36 BCR CDKN2A AFF1 ABL1 ETV6 FLT3
5 mortality/aging MP:0010768 10.33 CDKN2A AFF1 AUTS2 ABL1 BCR HLF
6 immune system MP:0005387 10.32 ABL1 BCR CDKN2A AFF1 ETV6 FLT3
7 homeostasis/metabolism MP:0005376 10.31 BCR ABL1 GATA3 ETV6 HLF FLT3
8 endocrine/exocrine gland MP:0005379 10.29 ABL1 AFF1 CDKN2A GATA3 ETV6 FLT3
9 embryo MP:0005380 10.26 ABL1 CDKN2A GATA3 ETV6 KMT2A PDGFRA
10 digestive/alimentary MP:0005381 10.17 BCR ABL1 CDKN2A GATA3 ETV6 PDGFRA
11 nervous system MP:0003631 10.17 ABL1 BCR CDKN2A AFF1 AUTS2 HLF
12 craniofacial MP:0005382 10.12 ABL1 GATA3 PBX1 PAX5 PDGFRA KMT2A
13 neoplasm MP:0002006 10.07 CDKN2A ETV6 FLT3 KMT2A PAX5 PDGFRA
14 integument MP:0010771 10.06 GATA3 ETV6 CDKN2A KMT2A PBX1 PDGFRA
15 liver/biliary system MP:0005370 10.03 BCR ABL1 CDKN2A KMT2A PBX1 RUNX1
16 no phenotypic analysis MP:0003012 10.03 CDKN2A AFF1 AUTS2 FLT3 KMT2A GATA3
17 hearing/vestibular/ear MP:0005377 10 BCR GATA3 KMT2A PBX1 PAX5 TP53
18 normal MP:0002873 9.93 ABL1 BCR ETV6 KMT2A GATA3 PAX5
19 renal/urinary system MP:0005367 9.5 BCR GATA3 KMT2A PBX1 PDGFRA TCF3
20 skeleton MP:0005390 9.32 ABL1 CDKN2A GATA3 FLT3 PAX5 PDGFRA

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic 3

Drugs for Leukemia, Acute Lymphoblastic 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 527)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tranexamic Acid Approved Phase 4 1197-18-8 5526
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
3
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
4
Fospropofol Approved, Illicit, Investigational Phase 4 258516-89-1, 258516-87-9 3038497
5
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 137-58-6 3676
6
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
7
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
8
Phenol Approved, Experimental Phase 4 108-95-2 996
9
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
10
Racepinephrine Approved Phase 4,Phase 2,Phase 3 329-65-7 838
11
Ledipasvir Approved Phase 4 1256388-51-8 67505836
12
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
13
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
14
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
15
Nicotine Approved Phase 4,Phase 1,Phase 2,Not Applicable 54-11-5 942 89594
16
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
17
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
18
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
19
Interferon beta-1b Approved Phase 4 145155-23-3
20
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
21
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
22
Azelastine Approved Phase 4 58581-89-8 2267
23
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 90566-53-3 62924
24
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1 75614-87-8, 51-45-6 774
25
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
26
Angiotensin II Approved, Investigational Phase 4,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
27
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
28
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
29
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 23994
30
Adalimumab Approved Phase 4,Phase 2,Phase 3 331731-18-1 16219006
31
Methotrexate Approved Phase 4,Phase 2,Phase 3 1959-05-2, 59-05-2 126941
32
Tofacitinib Approved, Investigational Phase 4,Phase 3 477600-75-2
33
Etanercept Approved, Investigational Phase 4,Phase 3 185243-69-0
34
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
35
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
36
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2 198153-51-4 5360545
37
Ribavirin Approved Phase 4,Phase 2 36791-04-5 37542
38
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
39
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
40
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
41
Infliximab Approved Phase 4 170277-31-3
42
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
45 Apricot Approved, Nutraceutical Phase 4
46
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
47
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
48 Antifibrinolytic Agents Phase 4
49 Coagulants Phase 4,Phase 3,Phase 1
50 Hemostatics Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 346)
# Name Status NCT ID Phase Drugs
1 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
2 Laparo-endoscopic Single Site (LESS) Cholecystectomy Versus Standard LAP-CHOLE Unknown status NCT01339325 Phase 4
3 Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol Completed NCT01401049 Phase 4 Fospropofol;Propofol/Lidocaine
4 PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam) Completed NCT00703885 Phase 4 0.25 mg alprazolam;1.0 mg alprazolam;placebo
5 A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age Completed NCT02580201 Phase 4
6 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
7 Adrenal Cortical Function and Vitamin A Deficiency in Sepsis Completed NCT03152474 Phase 4 Solumedrol 20mg;Vitamin A 100,000 IU
8 Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs Completed NCT02347345 Phase 4 Harvoni (Fixed dose combination ledipasvir/sofosbuvir)
9 APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3 Completed NCT00138034 Phase 4
10 UW-CTRI Triple Medication Smoking Cessation Study Completed NCT02681510 Phase 4 Varenicline;Nicotine Transdermal Patch;Nicotine Mini
11 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed NCT01317004 Phase 4 Fingolimod;Standard MS DMT
12 A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 Completed NCT01578330 Phase 4 Fingolimod
13 Effectiveness Of Therapy With A Thermal Water Nasal Aerosol In Children With Seasonal Allergic Rhinitis Completed NCT01326247 Phase 4
14 Memantine for Spasticity in MS Patients Completed NCT00638027 Phase 4 placebo;memantine
15 A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease Completed NCT00140621 Phase 4 Agalsidase beta
16 Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid Completed NCT00845195 Phase 4 Olopatadine HCl Nasal Spray, 0.6%;Azelastine HCl Nasal Spray, 0.1%
17 Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial Completed NCT00691665 Phase 4 Olopatadine HCL Nasal Spray, 0.6%;Fluticasone Propionate Nasal Spray, 50 mcg
18 Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate Completed NCT01847651 Phase 4 LOLA or placebo
19 A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer Completed NCT01094184 Phase 4 Bevacizumab;Paclitaxel;Docetaxel
20 A Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies Completed NCT00566774 Phase 4
21 A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982) Completed NCT01728584 Phase 4 Rocuronium;Sugammadex
22 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
23 A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus® Completed NCT00391027 Phase 4 Insulin Glargine (Lantus®);Inhaled Human Insulin (Exubera®)
24 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years Completed NCT01362439 Phase 4 Paliperidone ER
25 An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate Completed NCT02187055 Phase 4 Tofacitinib with methotrexate;Tofacitinib without methotrexate
26 Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis Completed NCT00913458 Phase 4 etanercept
27 Emervel for the Correction of Lower Face Wrinkles & Folds Completed NCT02718040 Phase 4
28 This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus Completed NCT00418522 Phase 4 Insulin glargine;Inhaled Insulin (Exubera)
29 Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection Recruiting NCT03057847 Phase 4 Sofosbuvir/Velpatasvir
30 A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study) Recruiting NCT03093480 Phase 4
31 Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies Recruiting NCT03103542 Phase 4
32 Topical Antibiotic Prophylaxis for Eyelids Recruiting NCT03199911 Phase 4 Topical Anti-Infective Product;Topical Ointment
33 HPV Antibody Response After GARDASIL 9 Vaccination in Participants After Allogeneic Stem Cell Transplantation Recruiting NCT03023631 Phase 4
34 Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World" Enrolling by invitation NCT02878161 Phase 4 methotrexate(necessary);leflunomide (permitted, not necessary);NSAIDs (permitted,not necessary);Glucocorticoids (permitted,not necessary)
35 A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis Terminated NCT00680316 Phase 4 Dornase alfa;Placebo
36 An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery Terminated NCT00766506 Phase 4
37 Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism Withdrawn NCT01415141 Phase 4 Peginterferon alfa-2a;Ribavirin;telaprevir
38 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
39 Addition of Pyridoxine to Prednisolone in Infantile Spasms Unknown status NCT01828437 Phase 3 Pyridoxine plus prednisolone;Prednisolone
40 Efficacy Study of Community-Based Treatment of Serious Bacterial Infections in Young Infants Unknown status NCT00189384 Phase 3 ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin
41 Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer Completed NCT00567554 Phase 3 epirubicin - cyclophosphamide / docetaxel;epirubicin - cyclophosphamide / docetaxel + bevacizumab;paclitaxel;paclitaxel + everolimus (RAD001);epirubicin - cyclophosphamide / docetaxel + trastuzumab;epirubicin - cyclophosphamide / docetaxel + lapatinib
42 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura Completed NCT02553317 Phase 3
43 Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children Completed NCT00383123 Phase 3
44 Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors Completed NCT00566852 Phase 3 Memantine
45 Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis Completed NCT00650078 Phase 3 MR prednisone;Placebo
46 Stepped Care to Optimize Pain Care Effectiveness Completed NCT00926588 Phase 3 Stepped care
47 A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine Completed NCT00472303 Phase 3 Tapentadol Extended Release;Matching Placebo after Tapentadol in the Titration Phase.;Morphine Sulphate Controlled Release
48 Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children Completed NCT00764790 Phase 3
49 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children Completed NCT01148459 Phase 3
50 Ibuprofen Extended-Release Dental Pain Study Completed NCT00707057 Phase 3 Ibuprofen 600 mg Extended-Release Tablets;Placebo

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic 3

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Leukemia, Acute Lymphoblastic 3

Genetic tests related to Leukemia, Acute Lymphoblastic 3:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to, 3 29 PAX5

Anatomical Context for Leukemia, Acute Lymphoblastic 3

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic 3:

41
B Cells, Brain, Testes, Prostate, Liver, Lung, Heart

Publications for Leukemia, Acute Lymphoblastic 3

Articles related to Leukemia, Acute Lymphoblastic 3:

# Title Authors Year
1
Precursor B-Cell Acute Lymphoblastic Leukemia/Lymphoma with L3 Morphology, Philadelphia Chromosome, MYC Gene Translocation, and Coexpression of TdT and Surface Light Chains: A Case Report. ( 23533894 )
2013

Variations for Leukemia, Acute Lymphoblastic 3

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic 3:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PAX5 NM_001280547.1(PAX5): c.547G> A (p.Gly183Ser) single nucleotide variant risk factor rs398123063 GRCh37 Chromosome 9, 37002702: 37002702
2 PAX5 NM_001280547.1(PAX5): c.547G> A (p.Gly183Ser) single nucleotide variant risk factor rs398123063 GRCh38 Chromosome 9, 37002705: 37002705
3 PAX5 NM_016734.2(PAX5): c.1013-1G> A single nucleotide variant Uncertain significance GRCh37 Chromosome 9, 36846927: 36846927
4 PAX5 NM_016734.2(PAX5): c.1013-1G> A single nucleotide variant Uncertain significance GRCh38 Chromosome 9, 36846930: 36846930

Expression for Leukemia, Acute Lymphoblastic 3

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic 3.

Pathways for Leukemia, Acute Lymphoblastic 3

Pathways related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.44 ABL1 BCR CDKN2A FLT3 PDGFRA RUNX1
2 12.37 GATA3 PAX5 PBX1 RUNX1 TCF3
3 12.31 ABL1 CDKN2A FOXP1 PDGFRA TP53
4 12.22 ABL1 BCR CDKN2A FLT3 PDGFRA RUNX1
5 12.17 CDKN2A HLA-C PDGFRA TCF3 TP53
6 11.95 ABL1 BCR FLT3 PDGFRA
7 11.75 CDKN2A KMT2A TP53
8 11.75 CDKN2A PDGFRA TCF3 TP53
9 11.63 GATA3 PBX1 TP53
10 11.55 AFF1 ETV6 FLT3 KMT2A PAX5 PBX1
11 11.51 FLT3 PDGFRA TP53
12
Show member pathways
11.48 ABL1 BCR PDGFRA
13 11.38 CDKN2A PDGFRA TP53
14 10.84 ABL1 CDKN2A TP53
15
Show member pathways
10.78 ABL1 CDKN2A TP53

GO Terms for Leukemia, Acute Lymphoblastic 3

Cellular components related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 ABL1 CDKN2A FOXP1 GATA3 KMT2A PAX5
2 protein-containing complex GO:0032991 9.55 ABL1 BCR FLT3 PDGFRA TP53
3 nucleus GO:0005634 9.55 ABL1 AFF1 AUTS2 CDKN2A ETV6 FLT3

Biological processes related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.99 CDKN2A GATA3 KMT2A RUNX1 TCF3 TP53
2 cell differentiation GO:0030154 9.97 ABL1 ETV6 FLT3 FOXP1 PAX5 PBX1
3 protein autophosphorylation GO:0046777 9.85 ABL1 BCR FLT3 PDGFRA
4 peptidyl-tyrosine phosphorylation GO:0018108 9.84 ABL1 BCR FLT3 PDGFRA
5 regulation of transcription, DNA-templated GO:0006355 9.8 ABL1 AFF1 AUTS2 CDKN2A ETV6 FOXP1
6 post-embryonic development GO:0009791 9.77 ABL1 GATA3 KMT2A
7 animal organ morphogenesis GO:0009887 9.76 GATA3 PAX5 PBX1 PDGFRA
8 transcription by RNA polymerase II GO:0006366 9.76 ETV6 GATA3 HLF KMT2A PAX5 PBX1
9 positive regulation of endothelial cell migration GO:0010595 9.7 ABL1 FOXP1 GATA3
10 thymus development GO:0048538 9.67 ABL1 GATA3 PBX1
11 spleen development GO:0048536 9.65 ABL1 KMT2A PBX1
12 regulation of hematopoietic stem cell differentiation GO:1902036 9.65 ABL1 GATA3 KMT2A RUNX1 TCF3
13 cell activation GO:0001775 9.62 GATA3 PDGFRA
14 definitive hemopoiesis GO:0060216 9.62 BCR KMT2A
15 positive regulation of histone H3-K4 methylation GO:0051571 9.61 AUTS2 KMT2A
16 replicative senescence GO:0090399 9.61 CDKN2A TP53
17 platelet-derived growth factor receptor signaling pathway GO:0048008 9.61 ABL1 BCR PDGFRA
18 hematopoietic stem cell proliferation GO:0071425 9.6 ETV6 RUNX1
19 regulation of histone H3-K4 methylation GO:0051569 9.58 GATA3 KMT2A
20 regulation of B cell receptor signaling pathway GO:0050855 9.58 PAX5 RUNX1
21 embryonic hemopoiesis GO:0035162 9.58 GATA3 KMT2A PBX1
22 negative regulation of ubiquitin-protein transferase activity GO:0051444 9.57 ABL1 CDKN2A
23 positive regulation of transcription by RNA polymerase II GO:0045944 9.36 AUTS2 CDKN2A ETV6 GATA3 HLF KMT2A
24 transcription, DNA-templated GO:0006351 10.15 AUTS2 CDKN2A ETV6 FOXP1 GATA3 HLF
25 phosphorylation GO:0016310 10.03 ABL1 BCR CDKN2A FLT3 PDGFRA PIP4K2A

Molecular functions related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.97 ABL1 BCR CDKN2A FLT3 PDGFRA PIP4K2A
2 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.85 ETV6 FOXP1 GATA3 HLF KMT2A PAX5
3 transcription regulatory region DNA binding GO:0044212 9.84 GATA3 KMT2A RUNX1 TP53
4 protein tyrosine kinase activity GO:0004713 9.78 ABL1 BCR FLT3 PDGFRA
5 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.77 ETV6 GATA3 HLF PAX5 PBX1
6 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding GO:0001228 9.76 GATA3 HLF RUNX1 TP53
7 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.73 ETV6 GATA3 PAX5 PBX1 TCF3 TP53
8 DNA binding GO:0003677 9.73 ABL1 CDKN2A ETV6 FOXP1 GATA3 HLF
9 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.72 ETV6 GATA3 HLF PBX1 RUNX1
10 protein self-association GO:0043621 9.69 FLT3 FOXP1 TP53
11 core promoter sequence-specific DNA binding GO:0001046 9.58 GATA3 KMT2A TP53
12 vascular endothelial growth factor-activated receptor activity GO:0005021 9.52 FLT3 PDGFRA
13 DNA binding transcription factor activity GO:0003700 9.36 AFF1 ETV6 FOXP1 GATA3 HLF KMT2A
14 protein binding GO:0005515 10.39 ABL1 AFF1 AUTS2 BCR CDKN2A ETV6

Sources for Leukemia, Acute Lymphoblastic 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....